Novel therapeutics for macrophage-driven inflammatory diseases via nicotinic acetylcholine receptor signaling

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10563
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Anesthesiology
• Research Institution: Wakayama Medical University
• Principal Investigator: Kishioka Shiroh 和歌山県立医科大学, 医学部, 教授 (60137255)
• Co-Investigator(Kenkyū-buntansha): 雑賀 史浩 和歌山県立医科大学, 医学部, 助教 (10644099) ; 深澤 洋滋 関西医療大学, 保健医療学部, 准教授 (70336882)
• Co-Investigator(Renkei-kenkyūsha): KIGUCHI Norikazu 和歌山県立医科大学, 医学部, 講師 (90433341)
• Research Collaborator: KOBAYASHI Daichi 和歌山県立医科大学, 医学部, 特別研究員
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 慢性炎症 / マクロファージ / フェノタイプ / サイトカイン / ニコチン受容体 / 神経障害性疼痛

Outline of Final Research Achievements

We determined the effects of nicotinic acetylcholine receptor (nAChR) signaling on regulation of macrophage phenotypes that contribute to chronic inflammatory disease such as neuropathic pain. Macrophages underlying neuropathic pain express nAChR, and nAChR ligands suppressed the production of inflammatory mediators in vivo and in vitro. Moreover, it is important that administration of nAChR ligands improved neuropathic pain. In conclusion, regulation of inflammatory macrophages through nAChR signaling may be effective pharmacotherapy for the relief of chronic inflammatory diseases.

Free Research Field

薬理学